Objective: To prepare and evaluate the suitable nanosuspensions of Meropenem (BCS-IV drug) to increase its solubility and dissolution. Methodology: The meropenem nanosuspensions were prepared by emulsification solvent evaporation technique by applying ultrasonic energy through probe sonicator, where the organic phase of drug solution in methanol was emulsified in aqueous phase containing hydroxy propyl methyl cellulose as solubilizer and sodium lauryl sulphate as stabilizer. The prepared nanosuspensions were characterised for particle size, zeta potential, surface morphology by SEM, drug excipient compatibility by FTIR and DSC and conducted in-vitro drug release studies. Results: Results showed that the prepared nanosuspensions were having particle size range from 1 to 1000nm and the zeta potential from -10 to -20 mVs. Scanning electron microscopic pictures revealed that the obtained nanosuspension particles were spherical in shape with surface smoothness and in-vitro drug release studies notified that the prepared nanosuspensions showed increase in solubility and dissolution of meropenem when compared with the pure form. Conclusion: The nanosuspensions of meropenem could be successfully prepared and can be concluded that the nanosuspension formulation is a promising approach to increase the solubility and dissolution of BCS-IV drugs like meropenem.
INTRODUCTION
Oral route is the most common and popular route for administration of drugs. 1 More than 40% of the new chemically synthesized drugs being generated through drug discovery programmers are poorly watersoluble or lipophilic compounds (BCS in class II and IV). 2 The uptake of poorly soluble drugs cannot be completed within the time at absorption site due to slow dissolution rate and generation of a low concentration gradient across the gastrointestinal tract leading to possibilities of gastric decomposition of drug due to longer gastrointestinal residence time and low bioavailability. 3 This type of drugs has always been a challenging problem to pharmaceutical scientists in formulating suitable dosage forms. 4 Solubility may be stated in units of concentration, molality, mole fraction, mole ratio, and other units. 5 Meropenem is a broad-spectrum carbapenem antibiotic 6 and classified as BCS class IV drug 7 means having low solubility and low permeability. Various approaches have be studied to overcome the solubility issues and unpleasant breath odour of active pharmaceutical ingredients belongs to BCS -II and IV. 8 Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, 9 which leads to cell death. Hence, there is a need to increase its solubility and dissolution of drug in the body fluids to increase its bioavailability. 
MATERIAL AND METHODS

Meropenem
Method of Preparation
Emulsification solvent evaporation method The Meropenem nanosuspensions were prepared by emulsification solvent evaporation technique. 10 Drug (400 mg) and HPMC (100 mg) was dissolved in 10 ml of DCM and methanol (solvent) (5 ml) at room temperature. This solution was poured into fixed amount (50 ml) of non-solvent (Water) containing SLS (100 mg) as surfactant stabilizer at the same temperature. Subject the mixture to ultrasonic waves for 15 minutes followed by mechanical stirring for 20 minutes. The prepared nanosuspension was left stirred for 1hr at room temperature to evaporate the organic solvent. Centrifuge the dispersion and collected the nanosuspension. Different formulations were prepared by changing the concentration of polymer. The formulation details of meropenem nanosuspensions are shown in Table 1 .
Evaluation Studies
Prepared nanosuspensions were evaluated for various characteristics.
Solubility Studies
The solubility studies on nanosuspensions were performed by adding the excess amount of dried nanosuspension powder to 10 ml phosphate buffer of pH 6.8. The sealed flasks were agitated on an orbital shaker for 12 hr at 37°C. Then samples were centrifuged at 8000 rpm for 10 min with high speed centrifuge (REMI R-8C, REMI laboratory Instruments, Bombay.) and the solutions were filtered using 0.45µ porous membrane filters before U.V analysis at 293 nm.
Drug -Excipient compatibility studies
The solid state characteristics of drug are known to have a significant influence on the solubility parameter. 11 Samples for analysis were prepared by mixing 50:50 ratio of drug and excipients. Then analysed by DSC (METTLER TOLEDO 822E equipment using E star software). The samples were taken separately in a pierced aluminium crucible with a capacity of 40 µl and evaluated in the temperature ranging from 25-250ºC at a heating of 10ºC/min with a stream of nitrogen. Drug excipient compatibility is further studied by FTIR spectroscopy (BRUKER Alpha, Bombay) in the wave number region of 400 to 4000 Cm -1 .
Particle Size
The particle size of nanosuspensions were measured using Malvern Zetasizer ZS200. The particle size has inverse relationship with solubility. 12 
Zeta potential
Zeta potential can greatly influence the stability of nanosuspensions. 4 For an electrostatic stability nanosuspension should have zeta potential a minimum of ±30mVs.For combined electrostatic and steric stabilization a minimum of ±20mV is required. The zeta potential of nanosuspension was measured using Malvern Zetasizer ZS200 at 25 ± 0.5ºC.
Drug Content
The nanosuspensions equivalent to 40 mg of drug was transferred to a volumetric flask (25 ml) dissolved and made up to 25 ml with methanol. Then suiable dilutions were made with phosphate buffer of pH 6.8 and drug content was analyzed against blank by UV spectrophotometer at 293 nm.
Entrapment efficiency
The freshly prepared nanosuspensions were centrifuged at 2000 rpm for 20 min at 25°C temperature using high speed centrifuge. The amount of incorporated drug was measured by taking the absorbance of the appropriately diluted 25 ml of supernatant solution at 293 nm using UV spectrophotometer against blank/control nanosuspensions. Entrapment efficiency was calculated using the following formula:
Morphological examination
The morphological examination of the prepared nanosuspension was studied by subjecting to SEM analysis.
Scanning electron microscopy (SEM)
The solid particle morphology of pure drug and nanosuspension were studied by using SEM analysis. A drop of drug nanosuspension was dispersed and mounted on aluminium stub covered with a glass lamella, air dried under vacuum and then examined. The SEM photo images were shown in Figure 5 .
Dissolution efficiency
Dissolution efficiency (DE 30min ) of nanosuspension at 30 min was calculated from the data of in vitro dissolution studies by using the following formula. 14 The obtained DE 30 values are shown in Table2.
In-vitro dissolution studies
In-vitro dissolution studies were performed by using USP apparatus IIRotating paddle (Electrolab-TDT-101, Bombay) using phosphate buffer pH 6.8 at 50 rpm speed and 37 ± 0.5°C temperature. Transferred 900 mL of dissolution medium into each of the vessels. After attaining the required temperature transferred nanosuspension equivalent to 40 mg of drug into each of the dissolution vessel and start immediately. At specific time points, withdrew 5 ml of the sample from each of the dissolution vessels. Filter the solution through 0.45 µm membrane filter. Maintain sink condition by adding 5 ml of the fresh buffer into each dissolution vessel immediately. Quantitative analysis of meropenem was performed using UV spectrophotometer (Shimatzu UV-1800) at 293 nm.
In vitro release kinetics
The mathematical models are used to evaluate the kinetics and mechanism of drug release from the nanosuspensions. The model that best fits the release data is selected based on the correlation coefficient (r 2 ) value in various models. Excipients increase drug dissolution rate by increasing active drug surface area in contact with the dissolution medium. 15 The correlation coefficient values of various kinetic models are shown in Table 2 . Stability studies were performed by storing the nanosuspensions at accelerated conditions as per ICH guidelines.
RESULTS AND DISCUSSION
Nano suspension approach is currently using method to enhance the solubility, dissolution rate there by bioavailability of poorly water soluble drugs. Nano suspensions consist of poorly water soluble drugs size below 1µm with or without any matrix material, 16 which are stabilized by surfactants and polymers. 17 In the present study various meropenem nanosuspensions were prepared by emulsification solvent evaporation technique. The formed nano formulations were almost spherical and uniform in size.
Solubility
The solubility studies performed for all the nanosuspension. The formulation F8 showed high solubility when compared to other formulations and it was clearly showed that increased in solubility of drug in nano form when compared with pure drug, it may be due to decrease in particle size and increased solubilisation.
Drug -Excipient compatibility studies
The DSC studies were performed for drug and drug-excipient mixture,it was found sharp endothermic peak at 129ºC in Figure 1 , which is due to the crystalline nature of drug. When DSC thermo gram of drug excipient mixture (figure 1) is compared with drug,it was observed that slight shift in the peak towards lower temperature is due to change in the physical state of drug on formulation. 18 DSC and FTIR studies (Figure 2 ) proved the absence of drug excipient interactions.
Particle size analysis
The particle size of meropenem nanosuspensions from all the formulations was found to be in the range of 2.0 to 1652.4 nm. Batch F8 had less particle size 2.0 nm as compared to other formulation and the particles are in uniform distribution as illustrated in Figure 3 .
Zeta potential
Zeta potential was measured by using Malvern Zetasizer ZS200. From the results of all the batches, optimized formulation F8 showed the zeta potential at 25 °C was -28.3 mV, zeta potential under ±30 mv shows good physical stability. 19 The Zeta potential of the optimized nanosuspensionformulation is given in Figure 4 .
Scanning Electron Microscopy
The nanosuspensions surface appearance and shape were analyzed by scanning Electron microscope (SEM). Figure 5 showed shape and surface appearance of the prepared nanosuspension and were found to be spherical in loose aggregates with surface smooth texture.
Drug content
The drug content was analysed for 10 formulations and the results were given in Table 2 . The drug content of all formulation was found to be in the range of 90.24% to 95.62% and these values are within the pharmacopoeial limit. 
Entrapment efficiency
The entrapment efficiency of 10 formulations were calculated. The % entrapment efficiency of all formulations was found in the range of 52.5% to 92.6%. Results of particle size, zeta potential, drug content, solubility, drug content, and entrapment efficiency were shown in Table 2 .
In vitro drug release studies and dissolution efficiency
It is evident from the in vitro drug release studies that, pure meropenem showed 8.6% of drug release at the end of 60 min it may be attributed to its higher hydrophobic and crystalline nature. Whereas the nanosuspension formulations showed more than 50% drug release at the end of 60 min. The optimized nanosuspension (F8) shows 97.7% drug release at the end of 60 min. The dissolution profiles of the pure drug and nanosuspensions are shown in the Figure 6 . The dissolution efficiency of all the formulations was calculated. The dissolution efficiency of optimized formulation was quite higher (92.6%) when compared to other formulations. From Table 2 , it was found that r 2 value of first order was greater than zero order value. The kinetic profiles of zero and first order 
Stability studies
The stability study results of nanosuspensions showed that there is no significant change with respect to the various parameters like particle size, moisture content, zeta potential, solubility and dissolution before and after storage for a period of 6 months as per ICH guidelines. Hence the nanosuspension are found to be stable at the normal room temperature.
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